TY - JOUR T1 - Lessons learned from an audit of the use of atorvastatin 80 mg for secondary prevention of cardiovascular disease in a tertiary hospital JF - Future Hospital Journal JO - Future Hosp J SP - s10 LP - s10 DO - 10.7861/futurehosp.3-2-s10 VL - 3 IS - Suppl 2 AU - Khoon-Sheng Kok AU - Timothy Gilbert Y1 - 2016/06/01 UR - http://www.rcpjournals.org/content/3/Suppl_2/s10.abstract N2 - To determine if all patients admitted with acute coronary syndrome (ACS) are initiated on atorvastatin 80 mg (Atorva80) ‘without delay’ as per NICE guidance issued in July 2014, unless contraindicated or a documented consultant decision.To determine if the above applied to patients already on a different statin therapy.To determine if patients had their liver function tests (LFTs) checked prior to initiating on Atorva80.This was a prospective audit of consecutive patients that attended the hospital with … ER -